mass 451.475 g/molPharmacokinetic dataBioavailability 65%Protein binding cardura dangers HepaticHalf life 22 hoursExcretion ?Therapeutic considerationsPregnancy cat. ?Legal status ? cardura dangers onlyRoutes oralDoxazosin mesylate, a quinazoline compound sold by Pfizer under the brand names Cardura® and Carduran® , is an alpha-1.

Cardura)Jump to: navigation, searchDoxazosinSystematic (IUPAC) name[4-(4-amino-6,7-dimethoxy- cardura dangers piperazin-1-yl]- (2,5-dioxabicyclo[4.4.0] deca-6,8,10-trien-4-yl) methanoneIdentifiersCAS number 74191-85-8ATC code C02CA04PubChem 3157DrugBank APRD00474Chemical dataFormula C23H25N5O5Mol. mass 451.475 g/molPharmacokinetic dataBioavailability 65%Protein binding 98%Metabolism HepaticHalf life 22 hoursExcretion cardura dangers ?Therapeutic considerationsPregnancy cat. ?Legal status ? Prescription onlyRoutes oralDoxazosin mesylate, a quinazoline compound sold by cardura dangers under the brand names cardura dangers and Carduran® , is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, cardura dangers the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha-1 adrenergic receptor blocker which inhibits the binding cardura dangers norepinephrine to alpha receptors in the autonomic cardura dangers system. The primary effect of this blockage is relaxed vascular smooth muscle tone.

hyperplasia.On February 22, 2005, the US FDA approved a sustained release form cardura dangers doxazosin, to be marketed.